The present disclosure relates to the field of oral mucoadhesive dosage forms and the type and amounts of structural components to improve mucoadhesion. The present disclosure further relates to combinations of active ingredients within a mucoadhesive dosage form.

Silver and titanium oxide nanoparticles produced with Fomes fomentarius or Fomitopsis pinicola aqueous extracts and methods for treating bacterial infections or cancer using them.

Described herein is a stable oral liquid pharmaceutical product comprising sodium picosulfate, magnesium oxide and citric acid. Particularly, sodium picosulfate is physically separated from magnesium oxide and citric acid prior to dispensing and is mixed at the time of administration.

Described herein is a stable oral liquid pharmaceutical product comprising sodium picosulfate, magnesium oxide and citric acid. Particularly, sodium picosulfate is physically separated from magnesium oxide and citric acid prior to dispensing and is mixed at the time of administration.

A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 .Math.m or less, and which may be homogeneous.

A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 .Math.m or less, and which may be homogeneous.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

The present invention pertains to the field of nutrition and medicine, and relates to a drug combination for anti-aging and its use. Specifically, the present invention relates to a drug combination comprising: 0.5 to 30 parts by weight of NR or its pharmaceutically acceptable salt, 0.5 to 30 parts by weight of NMN, and 0.01 to 35 parts by weight of mineral. The drug combination of the present invention has good anti-oxidative or anti-aging effects, and has excellent stability.

Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.